Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

s adverse events reported with PBT2.

"These results indicate that PBT2 is having an impact on the underlying biology of Alzheimer's, which is very exciting," Cummings said. "This is a critical proof of concept, and the safety and efficacy demonstrated by PBT2 in this study warrant evaluation in larger scale clinical trials in Alzheimer's."

A Phase IIb trial of a Tau Aggregation Inhibitor Therapy

As an alternative to anti-amyloid therapies for Alzheimer's, researchers continue to examine a variety of treatments and targets with the potential to curb the disease. This includes presenting data supporting the viability of therapies targeting tau protein and its aggregation into the "tangles" originally discovered by Alois Alzheimer.

Previous research has shown that the buildup of brain lesions known as neurofibrillary tangles, which are composed of a short fragment of a protein called tau, is correlated with increasing levels of dementia symptoms. And, these tangles first appear in the brain long before symptoms of the disease become clinically apparent. Methylthioninium chloride (MTC, or brand name rember(TM)) has been shown in the test tube to dissolve tau tangle filaments and prevent aggregation of tau into tangles. MTC has also been shown to block the toxic effects of aggregated tau in cells. In animal models, MTC has demonstrated cognitive and behavioral benefits in line with reduced tau pathology.

In research reported at ICAD 2008, Claude M. Wischik, Professor in Mental Health, University of Aberdeen, United Kingdom and Chairman, TauRx Therapeutics, Singapore, and colleagues conducted a 24-week, double-blind, randomized, dose-ranging, parallel design trial of MTC monotherapy in 321 people with Alzheimer's at 17 centers in the United Kingdom and Singapore, followed by a 60-week, blinded, active treatment extension. The control group received placebo for the initial 24 weeks and then a minimal efficacy dose subsequently. The primar
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Pa., May 31, 2011 Endo Pharmaceuticals (Nasdaq: ... and Alan Levin, executive vice president and chief financial officer ... Conference on Tuesday, June 7, 2011 at 9:00 a.m. ET. ... New York City, NY. A live webcast and ...
... CITY, Calif., May 31, 2011 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Don Wood, chief operations officer, ... Tuesday, June 7, 2011 at 11:30 a.m. ET at ... AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis ...
Cached Medicine Technology:
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... BASEL, Switzerland, Oct. 29 Roche (SWX: ROG.VX; RO.S),a ... it has extended its offer to acquire all of ... VMSI ),to 5:00 p.m., New York City time ... scheduled to expire at 5:00 p.m., New York City ...
... AIDS virus entered the United States via Haiti, probably arriving ... believed, according to new research. , After the virus, ... , "Our results show that the strain of virus ... around 1969. That is earlier than a lot of people ...
... or shorten the illness , MONDAY, Oct. 29 (HealthDay News) ... prevent pneumonia in elderly nursing home residents, a new study ... 617 people 65 and older in 33 nursing homes in ... blood zinc concentrations were about 50 percent less likely to ...
... produced responses in 40% of patients with Philadelphia, chromosome-positive chronic myeloid ... ... and availability in US means Novartis can offer physicians and ... EAST HANOVER, N.J., Oct. 29 Tasigna(R),(nilotinib) capsules have been approved in ...
... of Hepatitis C Treatment to Ongoing Oncology Program ... Ono Pharmaceutical,Co., Ltd. and Medarex, Inc. (Nasdaq: ... new drug application (IND) filed with the U.S. ... code of Ono,Pharmaceutical Co., Ltd.), a fully human ...
... Science,Corporation (Nasdaq: CSCX ), a global leader ... that it will present at the,18th Annual CIBC ... The,Company,s presentation is scheduled for Monday, November 5, ... and chief executive officer, will,review the Company,s business ...
Cached Medicine News:Health News:Roche Extends Tender Offer for Ventana 2Health News:Roche Extends Tender Offer for Ventana 3Health News:Roche Extends Tender Offer for Ventana 4Health News:HIV's path out of Africa: Haiti, the US then the world 2Health News:HIV's path out of Africa: Haiti, the US then the world 3Health News:Zinc Helps Elderly Ward Off Pneumonia 2Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 2Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 4Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 5Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 6Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 7Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 8Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 9Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 10Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 2
... closed dilution nebulizer allows the clinician to deliver ... gas into the side port for precise high ... P31000N, for normal flow patients, delivers 8-12 lpm ... the side port. For your high flow needs, ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
Rotary Piston Mini Nebulizer...
Rotary Piston Nebulizer...
Medicine Products: